Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
zalifrelimab (UGN-301)
i
Other names:
UGN-301, AGEN-1884, AGEN1884, RebmAb-600, AGEN 1884, RebmAb600, UGN301, RebmAb 600, UGN 301
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Agenus, Betta Pharma, Recepta, UroGen
Drug class:
CTLA4 antagonist
Related drugs:
‹
AGEN1181 (4)
JS007 (0)
TBio-6517 (0)
ALPN-202 (0)
AGEN1181 (4)
JS007 (0)
TBio-6517 (0)
ALPN-202 (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Cervical Cancer
No biomarker
Cervical Cancer
AGEN2034 + UGN-301
Sensitive: B - Late Trials
AGEN2034 + UGN-301
Sensitive
:
B
AGEN2034 + UGN-301
Sensitive: B - Late Trials
AGEN2034 + UGN-301
Sensitive
:
B
PD-L1 expression
Cervical Cancer
PD-L1 expression
Cervical Cancer
AGEN2034 + UGN-301
Sensitive: C3 – Early Trials
AGEN2034 + UGN-301
Sensitive
:
C3
AGEN2034 + UGN-301
Sensitive: C3 – Early Trials
AGEN2034 + UGN-301
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login